Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究

doi:10.3969/j.issn.1672-5069.2021.03.029

摘要/Abstract

摘要： 目的研究Viatorr覆膜支架用于经颈静脉肝内门体静脉分流术(TIPS)治疗肝硬化门静脉高压症患者的疗效和转归。方法 2018年1月～2020年1月我院收治的肝硬化并发门静脉高压症患者146例,采用随机数字表法将患者分为对照组73例和观察组73例,在接受TIPS术治疗时分别使用裸支架联合Fluency覆膜支架或Viatorr覆膜支架。随访12 m。结果观察组手术时间为(99.5±9.8)min,显著短于对照组【(110.0±8.5)min,P＜0.05】,术后两组门静脉压力均显著降低,但差异无统计学意义(P＞0.05);在术后3 m,两组肝功能指标变化无显著性差异(P>0.05);随访12 m,观察组分流道失效率为1.4%,显著低于对照组的23.3%(P＜0.05);观察组死亡5例(6.8%),对照组死亡6例(8.2%,Log-rank值=0.099,P=0.753)。结论相对于裸支架和Fluency覆膜双支架,使用Viatorr覆膜支架行TIPS术治疗肝硬化并发门脉高压症患者能有效缩短手术时间,保持分流道通畅,值得进一步观察。

关键词: 肝硬化, 门静脉高压症, 经颈静脉肝内门体静脉分流术, Viatorr覆膜支架, 治疗

Abstract: Objective The aim of this study was to investigate the application of Viatorr coated stent during the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of patients with liver cirrhosis and portal hypertension.Methods 146 patients with liver cirrhosis and portal hypertension were recruited in our hospital between January 2018 and January 2020, and were randomly divided into control (n=73) and observation (n=73) groups.All patients underwent TIPS, while the bare and the Fluency stent were used in patients in the control and the Viatorr stent was used in the observation. All patients were followed-up for 12 months.Results The operation time in the observation group was (99.5±9.8) min, significantly shorter than [(110.0±8.5) min, P<0.05] in the control, and there was no significant difference in portal vein pressure after operation between the two groups (P>0.05); at the end of 3 months after operation, there were no significant differences as respect to serum hepatic function tests between the two groups (P>0.05); at the end of 12 months, the shunt insufficiency rate in the observation group was 1.4%, significantly lower than 23.3% in the control group (P<0.05); five patients (6.8%)in the observation, and six(8.2%, Log-rank=0.099, P=0.753)in the control died.Conclusion The application of Viatorr covered stent during TIPS for treatment of cirrhotic patients with portal hypertension could effectively shorten the operation time and keep the shunt patency, which warrants further investigation.

Key words: Liver cirrhosis, Portal hypertension, Transjugular intrahepatic portosystemic shunt, Viatorr covered stent, Therapy

赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.

Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension[J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.

参考文献

[1] Chapin CA, Bass LM. Cirrhosis and portal hypertension in the pediatric population. Clin Liver Dis, 2018, 22(4):735-752.
[2]Hernández-Gea V, Baiges A, Turon F, et al. Idiopathic portal hypertension. Hepatology, 2018, 68(6):2413-2423.
[3] 刘满华, 周峰, 王晓兵,等. 116例经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症的随访研究. 中华肝脏病杂志, 2018, 26(8):596-600.
[4] Strunk H, Marinova M. Transjugular intrahepatic portosystemic shunt (TIPS): pathophysiologic basics, actual indications and results with review of the literature. Rofo, 2018, 190(8):701-711.
[5] Raissi D, Yu Q, Nisiewicz M, et al. Parallel transjugular intrahepatic portosystemic shunt with Viatorr © stents for primary TIPS insufficiency: case series and review of literature. World J Hepatol, 2019, 11(2):217-225.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[8] 中华医学会消化病学分会消化介入学组. 经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压共识意见. 中华消化杂志, 2014, 34(1):3-6.
[9] McNaughton DA, Abu-Yousef MM. Doppler US of the liver made simple. Radiographics, 2011, 31(1):161-88.
[10] 侯昌龙, 许军, 秦汉林, 等. 经颈静脉肝内门体分流术联合介入治疗肝癌伴门静脉高压症的疗效. 中华消化杂志, 2020, 40(7):474-479.
[11] Hung ML, Lee EW. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension: Review and update of the literature. Clin Liver Dis, 2019, 23(4):737-754.
[12] Busk TM, Bendtsen F, Poulsen JH, et al. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol, 2018, 314(2):G275-G286.
[13] Srinivasa RN, Srinivasa RN, Chick JFB, et al. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter. Cardiovasc Intervent Radiol, 2018, 41(3):518-521.
[14] Wan YM, Li YH, Xu Y, et al. Predictors of shunt dysfunction and overall survival in patients with variceal bleeding treated with transjugular portosystemic shunt creation using the fluency stent graft. Acad Radiol, 2018, 25(7):925-934.
[15] Qi X, Tian Y, Zhang W, et al. Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Therap Adv Gastroenterol, 2017, 10(1):32-41.
[16] Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience. Cardiovasc InterventRadiol, 2019, 42(1):78-86.
[17] Klinger C, Riecken B, Müller J, et al. Doppler ultrasound surveillance of TIPS-patency in the era of covered stents - retrospective analysis of a large single-center cohort. Z Gastroenterol, 2018, 56(9):1053-1062.
[18] KueiA, Mikolajczyk AE, Niemeyer MM. Hemolytic anemia following stent-graft transjugular intrahepatic portosystemic shunt creation. Semin Intervent Radiol, 2019, 36(2):72-75.
[19] McGregor H, Brunson C, Woodhead G, et al. Caudal migration and endovascular retrieval of two VIATORR CX stent grafts during transjugular intrahepatic portosystemic shunt placement. J Vasc Interv Radiol, 2020, 31(3):512-515.
[20] Coronado WM, Ju C, Bullen J, et al. Predictors of occurrence and risk of hepatic encephalopathy after TIPS creation: A 15-year experience. Cardiovasc Intervent Radiol, 2020, 43(8):1156-1164.